Mednet

Answering doctors' toughest questions with AI, medical literature, and real-world expertise.

[Mednet @themednet]

A full few days at #ASCO2026 - attending @Liza Henry’s panel discussion, hosting a great dinner for fellowship PDs, and talking with partners who share our belief that physicians should stay at the center of where oncology is headed. As always, oncologists are continuing the conversations on Mednet.

Check it out at https://t.co/MI2j49VwgI

[Mednet @themednet]

Our NYC team took on the city with a 90-minute mob-themed scavenger hunt through the streets of New York.

The gold medals were well-earned. Congrats to our winners! 🥇

#OurTeam #NYC #TeamBuilding

[Mednet @themednet]

Excited to see Nadine Housri, MD, speaking at the 6th Annual Virtual Wisconsin Primary CNS Malignancy Symposium today, April 24.

Her talk: “From Evidence to Judgment: Building AI for Real-World Oncology Decisions.”

A timely discussion on how AI can help bridge evidence and judgment in oncology care.

#Oncology #AIinHealthcare #BrainTumors #MedEd

[Mednet @themednet]

A big milestone for Mednet: our first-ever booth as a company at AAIM Week (@AAIMOnline).

It's been exciting to meet people in person, introduce Mednet AI, and hear thoughtful feedback from the community. It's been exciting to bring this next chapter of Mednet into the conference setting and connect with more than 200 attendees so far.

We're open through the last day today and grateful to everyone who has visited us.

#AIMW26 #AAIM #AcademicMedicine #MedicalEducation #GME #AIinMedicine

[Mednet @themednet]

The AI is only as good as the knowledge behind it.

Mednet AI is a clinical assistant built on a foundation ten years in the making — 40,000+ physicians and 3,400 academic experts.

➝ https://t.co/r5rO7vYemK

#MednetAI #AI #MedTwitter

[Mednet @themednet]

"Game-changer compared to traditional LLMs."

— Panicker Renni Robinson, MD, Cardiology Fellow

That's what Mednet AI was built for. Evidence + real expert opinion, combined. Free for all US physicians. ➝ https://t.co/r5rO7vYemK

#MednetAI #AI #MedTwitter

[Mednet @themednet]

@fumikochino @fumikochino ✅✅✅ from an AI hater is more than we could have hoped for! Thank you for sharing.

[Mednet @themednet]

@DrSpratticus @DrSpratticus play as much as you like! We'd love your feedback as we continue to evolve

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

I was impressed with @themednet's new AI tool. Preference for sources from high quality journals including guidelines, with additional tailored recs sourced from the extant expert content already present in Mednet. ✅✅✅ I'm a bit of an AI hater but thought this was useful.

[Mednet @themednet]

Most clinical assistants answer: what does the research say?

Mednet AI answers: what do experienced physicians actually do?

There's a difference. ➝ https://t.co/r5rO7vYemK

#MednetAI #AI #MedTwitter

[Mednet @themednet]

We've got big news!!

Mednet AI is now live — a clinical assistant informed by 10 years of real-world conversations from 40,000+ physicians, combined with the best of medical research.

Free for all Mednet physicians. Ask us anything. ➝ https://t.co/omhORHWuNp

#MednetAI #AI #MedTwitter

[Mednet @themednet]

New on IDSA - @PaulSaxMD interviews Patrick Passarelli (Dartmouth-Hitchcock; ID editor @themednet) on getting expert guidance beyond AI + what makes a great clinical question.

https://t.co/JWcJ1iHpFn

#IDTwitter #MedEd #InfectiousDiseases

[IDSA @IDSAInfo]

New #LetsTalkID!🎙️@PaulSaxMD talks w/ Patrick Passarelli, MD, a med-peds ID physician at @DartmouthHealth & ID editor of @themednet, about finding trusted expert guidance beyond AI and how clinician communities help shape real-world practice.

Transcript: https://t.co/xX9DYcMfxH

[Mednet @themednet]

@ASTRO_org Link to relevant Q&A:

In mCRPC patients who had an initial response to Pluvicto but progress within 12 months, where do you position PSMA radioligand retreatment relative to other next-line systemic options in your sequencing strategy?

https://t.co/LdhL8Ij5yZ

[Mednet @themednet]

The American Society for Radiation Oncology (@ASTRO_org) #MRPTS26 plenary session on Radiopharmaceutical Retreatment (Plenary II) just concluded.

Dr. Ana Kiess is answering questions now on theMednet.

Head to the Q&A → https://t.co/ZdsAiDUJOl

[Mednet @themednet]

@ASTRO_org Link to relevant Q&A:

What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?

https://t.co/ZdsAiDUJOl"

[Mednet @themednet]

@ASTRO_org @NeilTaunkMD Link to relevant Q&A:

Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?

https://t.co/ZnV9mWqT82

#MRPTS26

[Mednet @themednet]

The American Society for Radiation Oncology (@ASTRO_org) #MRPTS26 plenary session on Clinical Outcomes among Patients Treated with Lu-PSMA-617 and EBRT for Oligometastatic Prostate Cancer just concluded.

Dr. Neil K Taunk (@NeilTaunkMD) is answering questions now on theMednet.

[Mednet @themednet]

@ASTRO_org @NeilTaunkMD Link to relevant Q&A:

Can you give Pluvicto with concurrent palliative EBRT?

https://t.co/bATsbURrRP

#MRPTS26